BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12907440)

  • 1. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial.
    le Maignan C; Desablens B; Delwail V; Dib M; Berthou C; Vigier M; Ghandour C; Atmani S; Casassus P; Maisonneuve H; Le Mevel A; Traulle C; Bernard M; Briere J; Colonna P; Andrieu JM
    Blood; 2004 Jan; 103(1):58-66. PubMed ID: 12907440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
    Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
    J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N; Jais JP; Tomowiack C; Colombat P; Berthou C; Desablens B; Moles-Moreau MP; Gastinne T; Quittet P; Casassus P; Le Pourhiet-Le Mevel A; Ghandour C; Brière J; Colonna P; Andrieu JM
    Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
    Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
    Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
    Pavone V; Ricardi U; Luminari S; Gobbi P; Federico M; Baldini L; Iannitto E; Ucci G; Marcheselli L; Orsucci L; Angelucci E; Liberati M; Gavarotti P; Levis A;
    Ann Oncol; 2008 Apr; 19(4):763-8. PubMed ID: 18180244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
    J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
    N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
    Hamed RH; Anter AH; Awad IA
    Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
    Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K
    Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.
    Thomas J; Fermé C; Noordijk EM; Morschhauser F; Girinsky T; Gaillard I; Lugtenburg PJ; André M; Lybeert MLM; Stamatoullas A; Beijert M; Hélias P; Eghbali H; Gabarre J; van der Maazen RWM; Jaubert J; Bouabdallah K; Boulat O; Roesink JM; Christian B; Ong F; Bordessoule D; Tertian G; Gonzalez H; Vranovsky A; Quittet P; Tirelli U; de Jong D; Audouin J; Aleman BMP; Henry-Amar M
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1133-1145. PubMed ID: 29229324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
    Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
    Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABVD vs. radiotherapy in early stage Hodgkin's lymphoma: A critical look at the NCIC HD.6 trial.
    Wenz F; Abo-Madyan Y; Welzel G; Giordano FA
    Strahlenther Onkol; 2012 Aug; 188(8):649-52. PubMed ID: 22729282
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
    Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E
    Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABVD or BEACOPP
    Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
    Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
    Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.